SG11202103801UA - Method for the treatment of myasthenia gravis - Google Patents

Method for the treatment of myasthenia gravis

Info

Publication number
SG11202103801UA
SG11202103801UA SG11202103801UA SG11202103801UA SG11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA
Authority
SG
Singapore
Prior art keywords
treatment
myasthenia gravis
gravis
myasthenia
Prior art date
Application number
SG11202103801UA
Inventor
Melissa Kaye Brock
William James Byrnes
Bernhard Heinrich Greve
Claus Peter Kiessling
Grant Langdon
Manis Elizabeth Webster
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of SG11202103801UA publication Critical patent/SG11202103801UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202103801UA 2018-10-16 2019-10-16 Method for the treatment of myasthenia gravis SG11202103801UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746174P 2018-10-16 2018-10-16
PCT/EP2019/078093 WO2020079086A1 (en) 2018-10-16 2019-10-16 Method for the treatment of myasthenia gravis

Publications (1)

Publication Number Publication Date
SG11202103801UA true SG11202103801UA (en) 2021-05-28

Family

ID=68290236

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103801UA SG11202103801UA (en) 2018-10-16 2019-10-16 Method for the treatment of myasthenia gravis

Country Status (14)

Country Link
US (1) US20220144941A1 (en)
EP (1) EP3866933A1 (en)
JP (1) JP2022512713A (en)
KR (1) KR20210078517A (en)
CN (1) CN113646051A (en)
AR (1) AR117653A1 (en)
AU (1) AU2019361247A1 (en)
BR (1) BR112021007092A2 (en)
CA (1) CA3116091A1 (en)
IL (1) IL282137A (en)
MA (1) MA53903A (en)
MX (1) MX2021004351A (en)
SG (1) SG11202103801UA (en)
WO (1) WO2020079086A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005021PA (en) 2017-12-13 2020-07-29 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
TW202233236A (en) * 2020-11-06 2022-09-01 美商健生生物科技公司 Fcrn antibodies and methods of use thereof
WO2023198806A1 (en) 2022-04-13 2023-10-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody
WO2023215587A1 (en) * 2022-05-05 2023-11-09 UCB Biopharma SRL Treatment of myasthenia gravis with zilucoplan
WO2023240216A1 (en) * 2022-06-11 2023-12-14 Inhibrx, Inc. Fcrn-binding polypeptides and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (en) 1987-07-01 1987-07-01 Novo Industri As immobilization
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (en) 1994-02-28 1996-05-03 Procedes Machines Speciales Device for centering and blocking a workpiece with a view to running it in using an expansion lapper.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
JP4603894B2 (en) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム Assays to identify antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005003169A2 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006118772A2 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
RU2515108C2 (en) 2005-08-19 2014-05-10 Эббви Инк Immunoglobulin with double variable domains and its applications
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
CA2722082C (en) 2008-04-25 2021-11-09 Christopher Tenhoor Fc receptor binding proteins
HUE033438T2 (en) 2008-09-26 2017-11-28 Ucb Biopharma Sprl Biological products
EP2453823B1 (en) 2009-07-14 2015-05-13 WaveTec Vision Systems, Inc. Ophthalmic surgery measurement system
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
EP3137504B1 (en) 2014-04-30 2023-05-10 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
HRP20231399T1 (en) 2015-01-30 2024-02-16 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies

Also Published As

Publication number Publication date
CA3116091A1 (en) 2020-04-23
AU2019361247A1 (en) 2021-05-27
BR112021007092A2 (en) 2021-08-03
AR117653A1 (en) 2021-08-25
MA53903A (en) 2021-08-25
MX2021004351A (en) 2021-05-31
WO2020079086A1 (en) 2020-04-23
US20220144941A1 (en) 2022-05-12
IL282137A (en) 2021-05-31
EP3866933A1 (en) 2021-08-25
KR20210078517A (en) 2021-06-28
JP2022512713A (en) 2022-02-07
CN113646051A (en) 2021-11-12

Similar Documents

Publication Publication Date Title
IL276917A (en) Process for the preparation of elobixibat
IL282137A (en) Method for the treatment of myasthenia gravis
IL274603A (en) Use of fcrn antagonists for treatment of generalized myasthenia gravis
EP3426748A4 (en) Method of increasing the density of a well treatment brine
IL283948A (en) Methods for the treatment of depression
GB202106894D0 (en) Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone)
EP3463461A4 (en) Methods for treatment of refractory generalized myasthenia gravis
GB201804594D0 (en) Bonegraft substituteand method of manufacture
IL281792A (en) Treatment methods
GB201802839D0 (en) Method of manufacture
EP3894768C0 (en) Methods of cryo-curing
HUE063118T2 (en) Process for the preparation of n-alkyl-nitratoethylnitramines
IL281254A (en) Process for the preparation of lenvatinib
IL281839A (en) Treatment methods
ZA202001536B (en) Method for the treatment of wastewaters
GB201815478D0 (en) Subsea apparatus
IL281727A (en) Target formation apparatus
SG11202105877YA (en) Method of treatment
EP3877361C0 (en) Process for the preparation of arylsulfonylpropenenitriles
PL3599256T3 (en) Process for the preparation of polyorganosiloaxnes
GB201917487D0 (en) Methods for the treatment of retinoblastoma
HK1254604A1 (en) Method of increasing the expression of ubiad1
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
IL278861B1 (en) Method for producing halogenated n-arylpyrazoles